- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Prestige Will License Trastuzumab Biosimilar to Cipla
Under terms of the agreement, Cipla will have exclusive rights to distribute and market Prestige’s trastuzumab biosimilar (HD201) in selected emerging markets.
Prestige Biopharma, a Singapore-based biopharmaceutical company, recently announced that it has entered into a licensing agreement with Cipla Limited. Under terms of the agreement, Cipla will have exclusive rights to distribute and market Prestige’s trastuzumab biosimilar (HD201) in selected emerging markets.
The biosimilar, referencing Roche’s Herceptin, is currently being investigated in a phase 3 study for the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Prestige plans to submit the proposed biosimilar for regulatory approval with the European Medicines Agency and with the FDA in 2019.
“We are very pleased to partner with Cipla to commercialize our lead biosimilar program in selected emerging markets. With this partnership, we made another important step towards a broad global availability of our trastuzumab biosimilar product,” said Lisa Park, CEO of Prestige, in a statement.
The agreement will focus on leveraging Cipla’s strong local presence as well as sales and marketing capabilities within the local markets. Through the agreement, Prestige will be responsible for the development, product registration, and commercial supply of the biosimilar, while Cipla will be responsible for the marketing and commercialization.
“Cipla has always stood for access to life-saving medicines, and through this partnership, we take this key drug to more countries and patients around the world. We will continue to focus on capitalizing on our strengths to ensure high-quality medicines to patients in keeping with our purpose of ‘Caring for Life,’” said Umang Vohra, managing director and global CEO of Cipla.
Other products currently being developed in Prestige’s pipeline include HD204, a potential bevacizumab biosimilar currently undergoing phase 1 and 3 trials, and PBP1502, a potential adalimumab biosimilar currently in a phase 1 trial. Potential biosimilars in preclinical development include denosumab, aflibercept, eculizumab, and ipilimumab molecules.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
